Trials / Unknown
UnknownNCT05779579
Study of HS-10517 in Chinese Adult Participants
A Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Primary Efficacy of HS-10517 in Chinese Adult Participants
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 340 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10517 Dose 1 | HS-10517 Dose 1+Ritonavir |
| DRUG | HS-10517 Dose 2 | HS-10517 Dose 2+Ritonavir |
| DRUG | HS-10517 Dose 3 | HS-10517 Dose 3+Ritonavir |
| DRUG | HS-10517 Dose 4 | HS-10517 Dose 4+Ritonavir |
| DRUG | Placebo | Dose level A of placebo |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2023-05-31
- Completion
- 2023-06-30
- First posted
- 2023-03-22
- Last updated
- 2023-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05779579. Inclusion in this directory is not an endorsement.